Distribution plan for miRview meso test (Mesothelioma diagnosis test)

Rosetta Genomics (the developer of the test) and Warnex Medical Laboratories (a life science company that provides services to the pharmaceutical and healthcare industries) announced an exclusive distribution agreement for Rosetta's diagnostic tests.  One of these tests is the miRview meso test which uses microRNA molecular technology to differentiate mesothelioma from other cancers in the lung.  The use of this new test could mean more accurate diagnosis and more efficient  treatment options for mesothelioma patients.

As a provider, I find myself hopeful when reading about new research and diagnostic tools for mesothelioma and other cancers.  I feel we are getting closer to better diagnostic tools, more effective treatments, higher quality of life, and my clients living longer.  I look forward to hearing more about this new test and the implications for the mesothelioma community.